Vericel (NASDAQ:VCEL) Sets New 52-Week Low at $18.30

Vericel Co. (NASDAQ:VCELGet Rating) hit a new 52-week low during trading on Wednesday . The company traded as low as $18.30 and last traded at $19.11, with a volume of 23303 shares trading hands. The stock had previously closed at $23.05.

Analyst Upgrades and Downgrades

VCEL has been the topic of a number of research reports. BTIG Research cut shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday. StockNews.com started coverage on shares of Vericel in a research note on Wednesday, October 12th. They set a “sell” rating on the stock. HC Wainwright decreased their price target on shares of Vericel from $53.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday. Truist Financial cut shares of Vericel from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Stephens started coverage on shares of Vericel in a research note on Thursday, October 13th. They set an “overweight” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $37.40.

Vericel Price Performance

The company’s 50-day moving average is $24.51 and its 200-day moving average is $26.57. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -62.25 and a beta of 1.99.

Institutional Investors Weigh In On Vericel

Hedge funds have recently modified their holdings of the stock. Capital Advisory Group Advisory Services LLC acquired a new stake in shares of Vericel in the first quarter worth approximately $76,000. Newbridge Financial Services Group Inc. raised its holdings in Vericel by 100,000.0% in the third quarter. Newbridge Financial Services Group Inc. now owns 2,002 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 2,000 shares during the period. Hardy Reed LLC purchased a new position in Vericel in the first quarter valued at approximately $103,000. Point72 Hong Kong Ltd purchased a new position in Vericel in the second quarter valued at approximately $73,000. Finally, Captrust Financial Advisors raised its holdings in Vericel by 43.4% in the second quarter. Captrust Financial Advisors now owns 3,313 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 1,002 shares during the period.

About Vericel

(Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Further Reading

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.